Zydus Lifesciences (BOM:532321) Cash-to-Debt : N/A (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Zydus Lifesciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Zydus Lifesciences's cash to debt ratio for the quarter that ended in Dec. 2023 was N/A.

The historical rank and industry rank for Zydus Lifesciences's Cash-to-Debt or its related term are showing as below:

BOM:532321' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.11 Med: 0.32 Max: 10.51
Current: 10.51

During the past 13 years, Zydus Lifesciences's highest Cash to Debt Ratio was 10.51. The lowest was 0.11. And the median was 0.32.

BOM:532321's Cash-to-Debt is ranked better than
77.19% of 1048 companies
in the Drug Manufacturers industry
Industry Median: 0.935 vs BOM:532321: 10.51

Zydus Lifesciences Cash-to-Debt Historical Data

The historical data trend for Zydus Lifesciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Zydus Lifesciences Cash-to-Debt Chart

Zydus Lifesciences Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Cash-to-Debt

Get a 7-Day Free Trial

0.11

0.15

0.24

0.83

1.01

Zydus Lifesciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															N/A	1.01	N/A	10.51	N/A

Competitive Comparison of Zydus Lifesciences's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Zydus Lifesciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zydus Lifesciences's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zydus Lifesciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Zydus Lifesciences's Cash-to-Debt falls into.

Zydus Lifesciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Zydus Lifesciences's Cash to Debt Ratio for the fiscal year that ended in Mar. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	12066	/	(11751	+	198)
	=	1.01

Zydus Lifesciences's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Do not have enough data to calculate Cash to Debt ratio.

Zydus Lifesciences (BOM:532321) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Zydus Lifesciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Zydus Lifesciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Zydus Lifesciences (BOM:532321) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zydus Lifesciences Ltd (BOM:532321) » Definitions » Cash-to-Debt

Traded in Other Exchanges

ZYDUSLIFE:India

Address

Scheme No. 63, Sarkhej-Gandhinagar Highway, Zydus Corporate Park, Survey No. 536, Near Vaishnodevi Circle, Khoraj (Gandhinagar), Ahmedabad, GJ, IND, 382481

Website

https://www.zyduslife.com

Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. The product portfolio of the group includes Active Pharmaceutical Ingredients, human formulations, Health and wellness, and Animal health and veterinary products. Its product brands include Aten, Falcigo, Nucoxia, Levoday, Metscore and Arzep among others. It has two segments Pharmaceuticals and Consumer Products. It generates majority of its revenue from the Pharmaceutical segment.

Zydus Lifesciences (BOM:532321) Headlines

No Headlines